Global Inflammatory Bowel Disease Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Inflammatory Bowel Disease Drugs Market Research Report 2024
Inflammatory bowel disease is a condition generally caused when immune system attacks harmless bacteria, virus, or food in the intestine. The most common inflammatory bowel diseases are ulcerative colitis and Crohns disease.
According to Mr Accuracy reports new survey, global Inflammatory Bowel Disease Drugs market is projected to reach US$ 27550 million in 2029, increasing from US$ 19820 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Inflammatory Bowel Disease Drugs market research.
Growth of the global inflammatory bowel disease drugs market size is majorly driven by rise in prevalence of ulcerative colitis and crohn’s disease. In addition, the growing occurrence of consciousness of the disease across the world are few of the aspects to develop the treatment for inflammatory bowel disease fuel the market growth. Furthermore, the availability of drugs such as infliximab, adalimumab, golimumab, and cetrolizumab for the treatment of inflammatory bowel disease drives the growth of the market. Moreover, as per the article published by NCBI 2020, it was estimated that there were 9 to 20 cases per 100,000 per year of ulcerative colitis and its prevalence is 156 to 291 cases per 100,000 per year in North America and Europe region. Thus, rising number of cases of ulcerative colitis lead to rise in demand for inflammatory bowel disease treatment significantly drives the inflammatory bowel disease drugs market growth. In addition, for instance, in March 2022, Pfizer Inc acquired Arena Pharmaceuticals Inc, a clinical stage company which develops innovative potential therapies for the treatment of inflammatory bowel disease. Arena’s portfolio involves promising development stage therapeutic candidates in gastroenterology and others. Thus, constant focus of market players to adopt growth strategies in order to launch new drugs is expected to boost the market growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Inflammatory Bowel Disease Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Abbott Laboratories
Biocon Ltd
Roche
Johnson and Johnson
Mylan Pharmaceuticals
Novartis AG
Pfizer
Quest Medical
Sanofi
Takeda Pharmaceutical
AbbVie Inc
Bristol Myers Squibb
Celltrion Healthcare
Eli-Lilly
Merck & Co, Inc
UCB S.A.
Segment by Type
Amino-salicylates
Antibiotics
Corticosteroids
Immunomodulators
Biologics
Others
Ulcerative Colitis
Crohns Disease
Indeterminate Colitis
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Inflammatory Bowel Disease Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Inflammatory Bowel Disease Drugs market is projected to reach US$ 27550 million in 2029, increasing from US$ 19820 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Inflammatory Bowel Disease Drugs market research.
Growth of the global inflammatory bowel disease drugs market size is majorly driven by rise in prevalence of ulcerative colitis and crohn’s disease. In addition, the growing occurrence of consciousness of the disease across the world are few of the aspects to develop the treatment for inflammatory bowel disease fuel the market growth. Furthermore, the availability of drugs such as infliximab, adalimumab, golimumab, and cetrolizumab for the treatment of inflammatory bowel disease drives the growth of the market. Moreover, as per the article published by NCBI 2020, it was estimated that there were 9 to 20 cases per 100,000 per year of ulcerative colitis and its prevalence is 156 to 291 cases per 100,000 per year in North America and Europe region. Thus, rising number of cases of ulcerative colitis lead to rise in demand for inflammatory bowel disease treatment significantly drives the inflammatory bowel disease drugs market growth. In addition, for instance, in March 2022, Pfizer Inc acquired Arena Pharmaceuticals Inc, a clinical stage company which develops innovative potential therapies for the treatment of inflammatory bowel disease. Arena’s portfolio involves promising development stage therapeutic candidates in gastroenterology and others. Thus, constant focus of market players to adopt growth strategies in order to launch new drugs is expected to boost the market growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Inflammatory Bowel Disease Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbott Laboratories
Biocon Ltd
Roche
Johnson and Johnson
Mylan Pharmaceuticals
Novartis AG
Pfizer
Quest Medical
Sanofi
Takeda Pharmaceutical
AbbVie Inc
Bristol Myers Squibb
Celltrion Healthcare
Eli-Lilly
Merck & Co, Inc
UCB S.A.
Segment by Type
Amino-salicylates
Antibiotics
Corticosteroids
Immunomodulators
Biologics
Others
Segment by Application
Ulcerative Colitis
Crohns Disease
Indeterminate Colitis
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Inflammatory Bowel Disease Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices